• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

How Effective are Pfizer and AstraZeneca Vaccines vs the Delta Variant?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • The Delta SARS-CoV-2 variant (B.1.617.2) has been detected across the globe, and is quickly becoming the dominant variant  
  • Bernal et al. (NEJM, 2021) estimated the effectiveness of the Pfizer and AstraZeneca vaccines against the delta variant 

METHODS: 

  • Test-negative case-control study 
  • Population 
    • All symptomatic sequenced cases of COVID-19 in England 
    • Vaccination data up through May 16, 2021 
  • Exposures 
    • Delta variant 
    • Predominant strain at time of study (B.1.1.7 or alpha variant) 
  • Study design 
    • Variants were identified using sequencing and on the basis of the spike (S) gene status 
  • Primary outcome 
    • Proportion of cases with either variant according to vaccination status 

RESULTS: 

  • 38,592 cases with linked sequencing data 

After 1 Dose  

  • Effectiveness of one dose of either Pfizer of AstraZeneca  
    • Against alpha: 48.7% (95% CI, 45.5 to 51.7) 
    • Against delta: 30.7% (95% CI, 25.2 to 35.7) 
  • Results were similar for one dose of either vaccine individually 

After 2 Doses 

  • Effectiveness of two Pfizer doses  
    • Against alpha: 93.7% (95% CI, 91.6 to 95.3) 
    • Against delta: 88.0% (95% CI, 85.3 to 90.1) 
  • Effectiveness of two AstraZeneca doses  
    • Against alpha: 74.5% (95% CI, 68.4 to 79.4) 
    • Against delta: 67.0% (95% CI, 61.3 to 71.8) 

CONCLUSION: 

  • The effectiveness of two doses of both Pfizer and AstraZeneca’s COVID-19 vaccines were only slightly lower against the delta variant 
  • There was a more marked difference in effectiveness if individuals had received only one dose 
  • The authors conclude 

Our finding of reduced effectiveness after the first dose would support efforts to maximize vaccine uptake with two doses among vulnerable groups in the context of circulation of the delta variant 

Bernal et al. (NEJM, 2021)

Learn More – Primary Sources

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Efficacy of the Novavax SARS-CoV-2 Vaccine Against UK and South African Variants
The Value of Vaccination for Those Previously Infected with SARS-CoV-2
Safety and Efficacy Data of BNT162b2 COVID-19 Vaccine
Safety and Efficacy of AstraZeneca Oxford’s COVID-19 Vaccine
COVID-19 mRNA Vaccine Effectiveness in the Real World Including in Those Partially Immunized

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site